Article thumbnail

Pharmacology of the Phosphate Binder, Lanthanum Carbonate

By Stephen JP Damment


Studies were conducted to compare the phosphate-binding efficacy of lanthanum carbonate directly with other clinically used phosphate binders and to evaluate any potential adverse pharmacology. To examine the phosphate-binding efficacy, rats with normal renal function and chronic renal failure received lanthanum carbonate, aluminum hydroxide, calcium carbonate, or sevelamer hydrochloride in several experimental models. Lanthanum carbonate and aluminum hydroxide markedly increased excretion of [32P]-phosphate in feces and reduced excretion in urine in rats with normal renal function (p < 0.05), indicating good dietary phosphate-binding efficacy. In rats with chronic renal failure, lanthanum carbonate and aluminum hydroxide reduced urinary phosphate excretion to a greater degree and more rapidly than calcium carbonate, which in turn was more effective than sevelamer hydrochloride. The potential to induce adverse pharmacological effects was assessed systematically in mice, rats, and dogs with normal renal function using standard in vivo models. There was no evidence of any adverse secondary pharmacological effects of lanthanum carbonate on the central nervous, cardiovascular, respiratory, or gastrointestinal systems. These studies indicate that lanthanum carbonate is the more potent of the currently available dietary phosphate binders. No adverse secondary pharmacological actions were observed in vivo in a systematic evaluation at high doses

Topics: Lrnf Laboratory Study
Publisher: Informa Healthcare
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2007). A comparative review of the efficacy and safety of established phosphate binders: Calcium, sevelamer, and lanthanum carbonate. Curr Med Res Opin.
  2. A comparative study of 2 new phosphate binders (sevelamer and lanthanum carbonate) in routine clinical practice.
  3. (1999). a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Kidney Int.
  4. (1990). Biochemistry of the Lanthanides.
  5. Bone metabolism and disease in chronic kidney disease.
  6. Cognitive function in stage 5 chronic kidney disease patients on hemodialysis: No adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy.
  7. Consistent control of mineral and bone disorder in incident hemodialysis patients.
  8. de Serre Patey NM, Drueke TB. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration.
  9. (2009). Dietary administration in rodent studies distorts the tissue deposition profile of lanthanum carbonate; brain deposition is a contamination artefact? Toxicol Lett.
  10. Does the phosphate binder lanthanum carbonate affect bone in rats with chronic renal failure?
  11. double-blind, placebo-controlled, dose-titration, phase III study assessing the efficacy and tolerability of lanthanum carbonate: A new phosphate binder for the treatment of hyperphosphatemia.
  12. (2006). Drug Discovery and Evaluation: Safety and Pharmacokinetic Assays.
  13. (1989). Electron microscopic study of the blood-brain barrier in rats with brain edema and encephalopathy due to acute hepatic failure. Gastroenterol Jpn.
  14. (2009). Gastrointestinal calcium absorption after ingestion of non calcium containing phosphate binders in a healthy rat model [Abstract FPO1859]. J Am Soc Nephrol.
  15. (1980). Gastrointestinal drugs. In: Review of Medical Pharmacology.
  16. (2004). Improving phosphate-binder therapy as a way forward. Nephrol Dial Transplant.
  17. (2000). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use.
  18. Is controlling phosphorus by decreasing dietary protein intake beneficial or harmful in persons with chronic kidney disease?
  19. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: A crossover study.
  20. Mineral metabolism, mortality, and morbidity224 S.J.P. Damment Renal Failure in maintenance hemodialysis.
  21. Multicenter prospective randomized, doubleblind comparative study between lanthanum carbonate and calcium carbonate as phosphate binders in Japanese hemodialysis patients with hyperphosphatemia.
  22. Phosphorus management in end-stage renal disease.
  23. (2005). Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns Study. Kidney Int.
  24. (1989). Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study.
  25. Relative in vitro efficacy of the phosphate binders lanthanum carbonate and sevelamer hydrochloride.
  26. (2003). S a c c h i e r o R , B e r l o v e D , B r e z z a n i A , H a n u s M , Z h o r o v E , Burke S. Lanthanum deposition in tissues of renal compromised rats fed lanthanum carbonate for 28 days [Abstract FPO658]. J Am Soc Nephrol.
  27. (2001). Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency. Nephrol Dial Transplant.
  28. Sevelamer hydrochloride, a phosphate binder, protects against deterioration of renal function in rats with progressive chronic renal insufficiency.
  29. (1994). Studies of the ultrastructure and permeability of the blood-brain barrier in the developing corpus callosum in postnatal rat brain using electron dense tracers.
  30. (2007). Systemic lanthanum is excreted in the bile of rats. Toxicol Lett.